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Abstract
Introduction: Involution of terminal duct lobular units (TDLUs), the structures that give rise to most breast cancers,
has been associated with reduced breast cancer risk. Data suggest that the etiology and pathogenesis of luminal A
and core basal phenotype (CBP) breast cancers differ, but associations with TDLU involution are unknown.
Accordingly, we performed a masked microscopic assessment of TDLU involution in benign tissues associated with
luminal A and CBP breast cancers diagnosed among women less than age 55 years.
Methods: Cases were participants in a population-based case-control study conducted in Poland. Increased TDLU
involution was defined as fewer acini per TDLU or shorter TDLU diameter. Luminal A was defined as estrogen
receptor (ER) positive and/or progesterone receptor (PR) positive and human epidermal growth factor receptor 2
(HER2) negative and CBP as negative for ER, PR, and HER2 with expression of basal cytokeratins or epidermal
growth factor receptor (EGFR). We performed logistic regression to evaluate associations between TDLU involution
and tumor subtypes, adjusted for clinical characteristics and breast cancer risk factors.
Results: Among 232 luminal A and 49 CBP cancers associated with evaluable TDLUs, CBP tumors were associated
with significantly greater average number of acini per TDLU (odds ratio (OR) = 3.36, 95% confidence interval (CI) =
1.36 to 8.32, P = 0.009) and larger average TDLU diameter (OR = 2.49, 95% CI = 1.08 to 5.74, P = 0.03; comparing
highest to lowest group, adjusted for age and study site).
Conclusions: We suggest that TDLU involution is less marked in benign tissues surrounding CBP as compared to
luminal A cancers, which may reflect differences in the etiology and pathogenesis of these tumor subtypes.
Introduction
Epidemiologic research has demonstrated that risk factor
associations for breast cancer vary by estrogen receptor
(ER) status [1-3]. Recent studies that have included more
detailed characterization of tumor markers suggest that
differences in risk factor associations between luminal A
cancers (ER and/or progesterone receptor (PR) positive
and human epidermal growth factor receptor 2 (HER2)
negative) and core basal phenotype (CBP) cancers (“triple
negative” for ER, PR and HER2 with expression of basal
cytokeratins or epidermal growth factor receptor
(EGFR)) account for much of this etiological heterogene-
ity. In a pooled analysis of 12 population-based studies
included in the Breast Cancer Association Consortium,
risk for luminal A cancers was inversely associated with
having had a live birth, younger age at first full-term
birth, and premenopausal obesity, whereas these factors
were not associated with risk for CBP cancers [4]. In con-
trast to luminal A cancers, CBP cancers occur more often
among African Americans, BRCA1 mutation carriers and
younger women, providing additional support for the
view that these tumors are etiologically different [5,6].
Luminal A and CBP cancers are distinguished by their
gene expression and immunohistochemical profiles [7-9].
These tumors may arise from different stem or progeni-
tor cells [10-12] and thus may develop via pathways that
diverge early in tumor development. In support of this
view, data suggest that the molecular characteristics of
benign tissue surrounding specific breast cancer subtypes
may be as distinctive as that of cancer tissue itself. Speci-
fically, invasive breast cancers arise from terminal duct
lobular units (TDLUs), and data suggest that the mRNA
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expression profiles of micro-dissected TDLUs surround-
ing ER positive and ER negative breast cancers differ
[13]. Other studies have found that mRNA expression in
benign tissues associated with CBP cancers demonstrate
a “wound signature”, which seems to reflect the charac-
teristic biology of these tumors (that is, epithelial
mesenchymal transition) [14]. Although molecular ana-
lyses of peritumoral tissues are providing evidence for
breast field effects (the presence of larger areas of mole-
cular alteration surrounding histologically confirmed
breast cancer foci), epidemiological data inter-relating
breast cancer risk factors, breast cancer subtypes and
characteristics of benign tissues surrounding cancers are
limited.
TDLU involution, as assessed morphologically, has been
hypothesized to be associated with breast cancer risk [15].
Analyses performed in the Mayo Clinic Benign Breast
Disease cohort and the Nurses’ Health Study support this
view [3,16]. We extend this hypothesis by proposing that
the pattern of TDLU involution, as defined by acini per
TDLU or TDLU diameter, over the life course differs in
breasts containing luminal A vs. CBP breast cancers.
Accordingly, we performed an exploratory masked histolo-
gical analysis of TDLU involution using benign tissues col-
lected in a population-based breast cancer case-control
study conducted in Poland, which included detailed




Data and biologic specimens for the current analysis
came from a population-based breast cancer case-control
study conducted in Warsaw and Łodz, Poland from 2000
to 2003, as previously described in detail [17]. Eligible
cases were women between the ages of 20 and 74 years
diagnosed pathologically with incident in situ or invasive
breast carcinoma. Control subjects were randomly
selected using a population-based database, frequency-
matched to cases on city and age in five-year categories.
A total of 2,386 cases (79% of eligible) and 2,502 controls
(69% of eligible) agreed to participate in the study and
provided informed consent. The study was approved by
the National Cancer Institute and local Institutional
Review Boards in Poland. Since the goal of the current
study was to compare TDLU involution between tumor
subtypes, controls were not included in the analysis.
At the time of routine pathological evaluation, we col-
lected one tumor block (T) and two “grossly” benign tissue
blocks, from peritumoral (PT; adjacent to but not touch-
ing the tumor) and distant regions from the tumors (DT;
at the periphery of the specimen) when possible. We
restricted the current analysis to luminal A and CBP can-
cers because these tumors are viewed as most divergent
with regard to etiology and pathogenesis. Benign tissue
blocks (PT or DT) were available for 804 cases having
these two tumor subtypes (83% of total luminal A and
CBP cases). Tumor characteristics and risk factors did not
differ significantly among cases with and without benign
tissue blocks. We further restricted our analysis to 385
cases younger than age 55 years (317 luminal A and 68
CBP) because at older ages, TDLUs are often not identifi-
able in tissue sections, particularly in the absence of exo-
genous hormone use or obesity (data not shown).
Risk factor assessment
We assessed breast cancer risk factors through a
detailed personal interview as described elsewhere
[17,18]. Factors evaluated included education, age at
menarche, age at menopause, parity, breastfeeding, mea-
sured body mass index (BMI), age at first full-term
birth, smoking, alcohol drinking, hormone replacement
therapy (HRT) use among postmenopausal women, and
family history of breast cancer.
Pathology of cases
We assessed tumor size, histologic type, grade, and axillary
lymph node status via clinical reports and independent
review (MES) [17].
Procedures used for construction of tissue microarrays
(TMAs) from invasive cancer tissues, immunohistochem-
ical staining and scoring are described in detail elsewhere
[18,19]. Previously, we assessed the expression of ER, PR,
HER2, EGFR and cytokeratin 5 (CK5) using three different
methods: (i) clinical reports of ER and PR (ii) immunohis-
tochemical staining for cases included in TMAs, and (iii)
AQUA™(HistoRx, Branford, CT), which is a quantitative
immunofluorescent method that provides continuous
measurement of expression levels [20]. Different measure-
ment techniques showed strong agreement as previously
reported [19]. For the current analysis, we classified
tumors as luminal A (ER+ and/or PR+, HER2-) or CBP
(ER-, PR-, HER2-, CK5+, and/or EGFR+) as previously
described [18].
Assessment of Terminal Duct Lobular Unit (TDLU)
involution
One pathologist (MES) microscopically reviewed hematox-
ylin and eosin stained sections of benign blocks to assess
characteristics of TDLUs, masked to all clinical and epide-
miologic data, including tumor marker expression and
subtype classification. To determine which TDLUs were
suitable for assessment, we applied a modification of cri-
teria proposed by Milanese et al. [16]. Specifically, we
assessed TDLUs which: 1) consisted of acini lined by sin-
gle luminal and myoepithelial cell layers; 2) displayed a
limited extent of metaplasia or dilatation of acini (we
excluded TDLUs in which 50% or more of the acini
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showed lumina three times the normal diameter or meta-
plastic epithelium), and 3) did not display benign breast
disease, such as adenosis or other entities as implied from
criteria above. However, we did not exclude TDLUs based
on epithelial cell size per se or number of acini. Accord-
ingly, some acini included in this analysis resemble the
hyperplastic enlarged lobular units illustrated by Lee et al.
[21].
We focused on two agnostic metrics of involution: aver-
age number of acini per TDLU and average TDLU dia-
meter (both inversely related to involution). For each slide,
we recorded the presence or absence of TDLUs; TDLU
“diameter”, defined as the maximal linear span of epithe-
lium (relative to 400 × microscopic fields, approximated in
0.25 increments) and number of acini per TDLU (0 to 10,
11 to 20, 21 to 30, 31 to 50, 51 to 100, > 100) (Figure 1).
We first conducted a pilot study of 200 slides and mea-
sured all identifiable TDLUs present (> 1,000). The aver-
age number of acini per TDLU and TDLU diameters
across all measured TDLUs did not vary significantly
when six or more TDLUs were evaluated (Additional
file 1, Figure S1). For the full review, we microscopically
reviewed slides beginning at one end and sequentially
categorizing up to 10 unselected TDLUs masked to other
data.
After completing the slide review, we performed a
masked repeat review of 30 randomly selected slides to
assess reproducibility; ratings were significantly corre-
lated (number of acini per TDLU, concordance = 77%,
P = 0.002; TDLU diameter, concordance = 71%, P =
0.008). TDLU involution variables were not significantly
different in PT and DT blocks (P > 0.1 for pair-wise dif-
ferences between PT and DT for both number of acini
per TDLU and TDLU diameter); therefore, we took the
average values from PT and DT blocks for each TDLU
variable if both were available. As expected, the average
number of acini per TDLU and the average TDLU dia-
meter showed strong correlation (r = 0.86, P < 0.0001).
Statistical analyses
To assess whether TDLU involution varied by molecular
characteristics of the cancers, we evaluated the relation-
ships between immunohistochemical status of ER, PR,
CK5 and EGFR in tumors (explanatory variables) and the
average number of acini per TDLU or the average TDLU
diameter (outcome variables) using likelihood ratio tests
and unconditional polytomous logistic regression. We
defined tertiles of the distribution of the average number
of acini per TDLU and the average TDLU diameter using
cut-points based on distributions among luminal A
tumors. Results, based on using maximal, median and
average values across TDLUs, were similar and, therefore,
we present only the average values. We also compared
continuous AQUA scores for ER, PR, EGFR and CK5
expression in invasive tumors [19], to the number of
acini per TDLU or TDLU diameter categories using the
Kruskal-Wallis test. To assess our main hypothesis, we
evaluated whether the level of TDLU involution varied
between luminal A and CBP cancers using adjusted logis-
tic regression models with tumor subtype (CBP vs. lumi-
nal A) as the outcome variable and number of acini per
TDLU or TDLU diameter as explanatory variables.
Adjustment variables included age (five-year interval),
study site, breast cancer risk factors (education, age at
menarche, age at menopause, parity, age at first full-term
birth, breastfeeding, HRT use among post-menopausal
women, BMI, and family history of breast cancer). To
evaluate which of several correlated tumor features
(a) (b) 
Figure 1 TDLU images. A: Minimal or no TDLU involution, characterized by densely clustered acini (magnification 5×); B: Marked TDLU
involution demonstrating TDLUs containing few acini surrounded by dense collagen (magnification 10×).
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(tumor size, histology, grade, and nodal status, tumor
subtype) were most important in driving the associations
with TDLU involution variables, we also fitted regression
models with average acini per TDLU or average TDLU
diameter as the outcome variable and tumor characteris-
tics as the explanatory variables.
We used SAS (version 9.1.3, SAS Institute, Inc., Cary,
NC, USA) software for all analyses.
Results
Characteristics of study population
Among the 385 cases younger than age 55 years, TDLUs
were identified in 281 cases (232 luminal A and 49
CBP). Distributions of risk factors and pathologic char-
acteristics did not differ significantly among cases with
and without evaluable TDLUs, overall or within subtype
(Additional file 1, Table S1).
Relationships of number of acini per TDLU and TDLU
diameter to individual tumor markers
First, we compared TDLU involution characteristics in
tumor subtypes defined by individual markers (ER, PR,
CK5, and EGFR), dichotomously categorized as negative
or positive, and adjusted for age and study site. Compared
with ER negative cases, ER positive cases were associated
with a significantly reduced number of acini per TDLU
(odds ratio (OR) = 0.34, 95% confidence interval (CI) =
0.17 to 0.70, P = 0.003, comparing the highest to the low-
est group), whereas EGFR positive tumors were associated
with a greater number of acini per TDLU than EGFR
negative tumors (OR = 2.78, 95% CI = 1.21 to 6.39, P =
0.02). CK5 positive cancers were also associated with
greater number of acini per TDLU than CK5 negative can-
cers, but the comparison was not statistically significant.
The number of acini per TDLU was not associated with
PR expression, tumor size, histological type, grade or axil-
lary node status (Table 1). Results for TDLU diameter
were similar to those for the number of acini per TDLU
(for ER: OR = 0.38, 95% CI = 0.19 to 0.76, P = 0.006; for
EGFR: OR = 2.95, 95% CI = 1.24 to 7.03, P = 0.01; com-
paring the highest to the lowest group).
Next, we evaluated relationships between TDLU involu-
tion characteristics and these tumor markers assessed as
continuous variables. Analyses comparing number of acini
per TDLU to continuous AQUA scores for ER, PR, and
EGFR expression demonstrated associations consistent
with those found in analyses in which markers were classi-
fied as negative or positive (Kruskal-Wallis test, P = 0.02
for ER and EGFR, P = 0.74 for PR, Figure 2).
Number of acini per TDLU and TDLU diameter in luminal
A vs. Core Basal Phenotype (CBP) cancers
The number of acini per TDLU and TDLU diameter
were significantly greater for CBP as compared with
luminal A tumors (Table 2). The associations remained
significant after adjustment for age and study site (num-
ber of acini per TDLU: OR = 3.36, 95% CI = 1.36 to
8.32, P = 0.009; TDLU diameter: OR = 2.49, 95% CI =
1.08 to 5.74, P = 0.03; comparing the highest to the low-
est group). Associations were equivalent or stronger in
analyses adjusted for multiple breast cancer risk factors
(education, age at menarche, age at menopause, parity,
age at first full-term birth, breastfeeding, HRT use
among post-menopausal women, BMI and family history
of breast cancer; for number of acini per TDLU: OR =
4.44, 95% CI = 1.58 to 12.51, P = 0.005) (Table 2).
When analyzing the correlated tumor characteristics
simultaneously, the associations with both number of
acini per TDLU and TDLU diameter were only observed
for tumor subtype (CBP vs. luminal A) but not for
tumor grade, histology, size, or nodal status (data not
shown).
Discussion
Studies have found that reduced TDLU involution is an
independent risk factor for breast cancer among women
biopsied for benign breast disease [3,16,22]. Herein, we
report results of a case-case comparison, showing that
cancers that are ER negative (as compared to ER positive)
or EGFR positive (as compared to EGFR negative) are
associated with a greater number of acini per TDLU and
larger TDLU diameters, consistent with reduced involu-
tion. Furthermore, based on immunohistochemical
tumor subtyping, we found that TDLUs associated with
CBP cancers are less involuted than those surrounding
luminal A cancers, even following adjustment for age and
other factors, including reproductive variables, BMI,
family history of breast cancer and clinical variables. Our
data are consistent with other studies showing that gene
expression profiles of TDLUs surrounding cancers vary
by the ER status of the tumor [13] and experimental evi-
dence that stromal-epithelial interactions differ for lumi-
nal A and CBP cancers [23]. Further studies are needed
to confirm these results and to determine whether these
findings reflect differences in the etiology and pathogen-
esis of luminal A and CBP cancers or a secondary influ-
ence of tumor growth on surrounding benign tissues.
Prior studies have found that TDLU involution is
directly associated with older age and inversely related to
parity and early age at menarche. Although parity is asso-
ciated with lower overall breast cancer risk, breast cancer
risk increases transiently following pregnancy. In addi-
tion, parity-related breast cancer risk has also been asso-
ciated with young age, having ER-negative tumors, late
first full-term births, and failure to breastfeed [24,25].
Mechanisms that may contribute to the development of
pregnancy-related cancers include exposure to elevated
hormones during pregnancy and inflammation related to
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Table 1 Relationship between average number of acini per TDLU and tumor characteristics among women < 55 years
old.
Average number of acini (tertiles)*
Tumor characteristics Low Middle High OR (95% CI)** P**
N % N % N %
Tumor size
≤ 2 cm 48 31.8 50 33.1 53 35.1 Ref
> 2 cm 40 31.0 40 31.0 49 38.0 1.15 (0.64, 2.06) 0.64
Axillary node metastases
Negative 54 34.2 47 29.7 57 36.1 Ref
Positive 32 27.1 41 34.8 45 38.1 1.31 (0.72, 2.38) 0.37
Histology
Ductal 49 27.5 56 31.5 73 41.0 Ref
Lobular 18 40.9 14 31.8 12 27.3 0.45 (0.20, 1.03) 0.06
Mixed 11 30.6 17 47.2 8 22.2 0.47 (0.17, 1.27) 0.13
Other 10 43.5 3 13.0 10 43.5 0.79 (0.30, 2.07) 0.62
Tumor grade
Well differentiated 25 36.2 19 27.5 25 36.2 Ref
Moderately differentiated 43 28.5 54 35.8 54 35.8 1.06 (0.56, 2.13) 0.88
Poorly differentiated 20 32.8 17 27.9 24 39.3 0.97 (0.42, 2.25) 0.95
ER
Negative 14 17.5 27 33.7 39 48.8 Ref
Positive 74 36.8 63 31.3 64 31.8 0.34 (0.17, 0.70) 0.003
PR
Negative 24 27.9 28 32.6 34 39.5 Ref
Positive 64 32.8 62 31.8 69 35.4 0.76 (0.40, 1.43) 0.39
CK5
Negative 72 34.6 64 30.8 72 34.6 Ref
Positive 16 22.9 24 34.3 30 42.9 1.72 (0.85, 3.49) 0.13
EGFR
Negative 79 34.1 78 33.6 75 32.3 Ref
Positive 9 19.1 10 21.3 28 59.6 2.78 (1.21, 6.39) 0.02
*Number of acini reflects averaged values from TDLUs per case in tertiles from lowest to highest; Number of acini per TDLU (1: 0 to 10, 2: 11 to 20, 3: 21 to 30, 4:
31 to 50, 5: 51 to 100, 6: > 100), low = 1 to 1.34; middle = 1.34 to 1.8; high = > 1.8. **P-values, ORs and 95% CIs were obtained from logistic regression analyses
comparing cases with the highest to the lowest tertile of number of acini per TDLU adjusted for age and study site.
Figure 2 Average number of acini per TDLU and marker expression levels in invasive tumors. ER, PR, and EGFR expression levels were
measured using AQUA™, which is a quantitative immunofluorescent method that provides continuous measurement of expression levels.
AQUA scores were transformed as previously described [19].
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postpartum involution [24]. Data also suggest that preg-
nancy may induce proliferation of progenitor cells
expressing basal markers [26], whereas long-term breast-
feeding, which reduces cancer risk, may decrease the
number of these cells by inducing terminal differentiation
[26,27]. Therefore, a full-term pregnancy followed by a
short duration of lactation may lead to retention of pro-
genitor cells and increased risk for CBP cancers. Consis-
tent with these findings, Symmans et al. found that
women who do not breastfeed for longer periods are at
increased risk of triple-negative breast cancers [28]. In a
recent study of African American women with breast
cancer, higher parity was associated with an increased
risk of ER-negative or PR-negative breast cancer, which
was mitigated by breastfeeding [29]. In this respect, our
finding that TDLU involution is less in CBP as compared
to luminal A cancers is consistent with the hypothesis
that CBP cancers are related to hyperplastic processes in
the breast that have not fully regressed postpartum.
Our findings may also have potential implications for
understanding racial disparities in breast cancer. Com-
pared to Caucasian women, African American women
undergo menarche at younger ages [30], have higher par-
ity [31], breastfeed less [6], and have higher rates of CBP
cancers. Thus, etiological differences between luminal A
and CBP breast cancers may reflect the effect and/or the
interaction of risk factors on TDLU involution, molecular
characteristics and function. Expansion of these results
would have potential implications for developing preven-
tion strategies because TDLU size could represent a bio-
marker for assessing breast cancer risk and perhaps the
effects of preventive interventions among women who
have been biopsied for benign breast diseases [16,22].
Our study is limited by the comparatively small sample
size, which provides modest power to evaluate associa-
tions between TDLU involution and breast cancer sub-
types. In addition, because our analyses uses tissues from
women with breast cancer, we cannot distinguish
whether TDLU morphology influences breast cancer risk
or reflects the influence of tumors on the surrounding
breast. However, the similarity of the TDLU morphology
in samples proximal and distal from the tumor may
weaken this argument because other field effects are
more pronounced in close proximity to cancer [32].
Another limitation of this case-only study design is that
we cannot obtain the relative risks associated with the
TDLU involution variables for each tumor subtype. How-
ever, acquiring appropriate resources, with the prospec-
tive collection of breast tissues prior to cancer diagnosis
and sufficient number of cases with CBP tumors devel-
oped afterwards, to obtain such risk estimates may be
challenging. Finally, we restricted our analysis to younger
women to avoid biases related to the ability to observe
TDLUs at later ages. Strengths of our study include the
population-based design, comprehensive collection of
breast cancer risk factors, detailed analysis of marker
expression using multiple methods, and availability of
cancer and non-cancer tissues collected for research. Our
TDLU assessment was subjective; however, our review
was masked and reproducible.
Conclusions
Our findings suggest that the morphology of TDLUs
associated with luminal A and CBP cancers varies,
which may reflect differences in the pathogenesis of
these etiologically distinctive tumors. Confirmation and
extension of these findings by performing molecular
analyses of TDLUs may provide insights into the patho-
genesis of different breast cancer subtypes and/or their
secondary effects on peritumoral tissues. Data suggest
that CBP cancers may have a high risk of local recur-
rence [33], which could reflect the presence of residual
abnormal epithelium remaining in the breast after initial
treatment. Accordingly, future studies to map TDLUs
for histopathological and molecular characterization
may have value for understanding the pathogenesis of
different subtypes of breast cancer and achieving trans-
lational goals.
Table 2 TDLU involution variables and tumor subtypes (CBP vs.
Involution Luminal A CBP
N % N % OR* 95% CI P ORadj** 95% CI P
#acini/TDLU
Tertile 1 81 34.9 7 14.3 Ref Ref
Tertile 2 74 31.9 16 32.6 2.55 0.98, 6.64 0.05 3.08 1.07, 8.89 0.04
Tertile 3 77 33.2 26 53.1 3.36 1.36, 8.32 0.009 4.44 1.58, 12.51 0.005
Size of TDLUs
Tertile 1 76 32.8 9 18.4 Ref Ref
Tertile 2 79 34.0 12 24.5 1.25 0.49, 3.16 0.64 1.35 0.47, 3.84 0.58
Tertile 3 77 33.2 28 57.1 2.49 1.08, 5.74 0.03 3.84 1.45, 10.13 0.007
Luminal A) among women < 55 years old.
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Additional material
Additional file 1: Supplementary figures and tables. Figure S1 and
Table S1.
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